| P/E (FY) | — | Sales (TTM) | $580.0M |
| Earnings (TTM) | -$721.6M | ROE | — |
| Net Margin | −145.98% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 86.30% |
BridgeBio Pharma is a biopharmaceutical company that discovers, develops, and delivers medicines for patients with genetic diseases. It offers Attruby, an oral TTR stabilizer for transthyretin amyloid cardiomyopathy, and Nulibry (fosdenopterin) for molybdenum cofactor deficiency, and is developing low-dose infigratinib for achondroplasia and hypochondroplasia and encaleret for autosomal dominant hypocalcemia type 1.
| Market Cap | $16.36B | Trading Days | 1776 |
| 52W High | 93.42 |
| 52W Low | 42.09 |
| % Off High | −10.57% |
| YTD | 9.22% | 1Y | 80.35% |
| 3Y | 138.62% | 5Y | 53.62% |
| Since incept. (ann.) | 16.94% |
Reportable 100%
| Ann. Volatility (1Y) | 49.15% | Ann. Volatility (3Y) | 52.70% |
| Sharpe (1Y) | 1.47 | Sharpe (3Y) | 0.83 |
| Max Drawdown (1Y) | −20.25% | Max Drawdown (3Y) | −49.08% |
| Beta (3Y, vs SPY) | 0.73 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | $16.06B | — |
| QNRX | Quoin Pharmaceuticals, Ltd. | $14.34B | — |
| ZLAB | Zai Lab Ltd | $20.06B | — |
| ELAN | Elanco Animal Health Inc | $13.18B | — |
| VTRS | Viatris Inc | $20.75B | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $12.61B | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $12.14B | — |
| UTHR | UNITED THERAPEUTICS Corp | $22.27B | 18.8 |
| INSM | INSMED Inc | $22.35B | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.86B | 34.1 |
| AXSM | Axsome Therapeutics, Inc. | $11.70B |
| ROIV | Roivant Sciences Ltd. | $23.64B | — |